166 related articles for article (PubMed ID: 36516271)
1. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
[TBL] [Abstract][Full Text] [Related]
2. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
3. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
Kasparek P; Ileninova Z; Zbodakova O; Kanchev I; Benada O; Chalupsky K; Brattsand M; Beck IM; Sedlacek R
PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
[TBL] [Abstract][Full Text] [Related]
4. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
5. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
[TBL] [Abstract][Full Text] [Related]
6. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
[TBL] [Abstract][Full Text] [Related]
7. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation.
Ramesh K; Matta SA; Chew FT; Mok YK
Allergy; 2020 Feb; 75(2):403-411. PubMed ID: 31407378
[TBL] [Abstract][Full Text] [Related]
8. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
Zingkou E; Pampalakis G; Sotiropoulou G
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
[TBL] [Abstract][Full Text] [Related]
9. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
[TBL] [Abstract][Full Text] [Related]
10. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
11. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
12. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A
J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
15. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
17. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
Meyer-Hoffert U; Wu Z; Kantyka T; Fischer J; Latendorf T; Hansmann B; Bartels J; He Y; Gläser R; Schröder JM
J Biol Chem; 2010 Oct; 285(42):32174-81. PubMed ID: 20667819
[TBL] [Abstract][Full Text] [Related]
18. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
Deraison C; Bonnart C; Lopez F; Besson C; Robinson R; Jayakumar A; Wagberg F; Brattsand M; Hachem JP; Leonardsson G; Hovnanian A
Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
[TBL] [Abstract][Full Text] [Related]
19. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
[TBL] [Abstract][Full Text] [Related]
20. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
